RJNMSR
Review Journal of Neurological & Medical Sciences Review

Volume 3, Issue 4, 2025

DECIPHERING MONKEY POX: A TRANSDISCIPLINARY REVIEW OF ITS EVOLUTIONARY ORIGINS, VIRAL MECHANISMS, CLINICAL DIVERSITY, AND THE ARCHITECTURE OF GLOBAL PREPAREDNESS

Muhammad Saad Masood[1], Shazia Gulzar[2], Aniqa Tariq[3], Syeda Kainat Ali[4], Nadia Gulzar[5], Sidra Jabeen[*6]

[1]*Sargodha Medical College, University of Sargodha*
[2]*Women University Bagh, Azad Kashmir*
[3]*Iqra University Chakshazad Campus Islamabad*
[4]*The Superior University Lahore, Sargodha Campus*
[5]*Iqra University Chakshazad Campus Islamabad*
[*6]*Department of Allied Health Sciences, The Superior University Lahore*

[*6]Sidra.jabeen.sgd@superior.edu.pk

Corresponding Author: *
Sidra Jabeen
DOI: https://doi.org/10.5281/zenodo.16882003

Received	Accepted	Published
03 May, 2025	01 July, 2025	15 August, 2025

ABSTRACT

Monkeypox is a zoonotic ailment resulting from the infection with the monkeypox virus, also known as MPXV, which became an important health issue of the present days. This review aims at giving a comprehensive update on monkeypox and discuss aspects such as history, virology, pathogenicity, clinical features, diagnosis, therapeutic measures and control. The recent outbreak in the global platform in the year 2024 has brought out the aspect of this formerly neglected tropical ailment to the light, thereby demanding further research and study. This article provides a state of art review of monkeypox, ongoing research and new directions in management and prevention of monkeypox as an emerging zoonotic disease. This paper is intended to be a reference for members of the healthcare profession and public health, and researchers, as a consolidation of evidence and existing and new knowledge surrounding monkeypox to allow for better preparedness and response strategies relating to the virus on a global scale.

Key Words: *Monkeypox, Orthopoxvirus, Poxviridae Infections, Smallpox, Zoonoses, Vaccinia virus, Emerging Infectious, Diseases, Human Monkeypox, Monkeypox virus, Viral Skin Diseases, Exanthema, Viral Hemorrhagic Fevers, Immunization, Reservoirs of Infection*

INTRODUCTION

BACKGROUND:

Monkeypox is which is a rare and a geographical restricted Zoonotic disease also became more popular in 2024 as it started spreading across the world. This is an orthopox virus infection from monkeypox virus (MPXV) discovered in 1958 in a research colony of monkeys and later reported in humans in 1970 in the DRC. Monkeypox virus for many years was endemic only in Central and West Africa occasionally seen in people who had traveled to the endemic region or came in contact with animals associated with the pathogen (Reynolds et al.
, 2019). Monkeypox epidemiology profile shifted in 2022, several countries in various continents were reporting cases; this was the largest virus outbreak outside endemic areas. This global

emergence brings out issues to do with the development of the virus, its mode of spread and the effectiveness of the current containment measures.

Monkeypox has been a different kettle of fish for the world's public health systems. Due to the clinical resemblance of the disease to other poxviruses such as the variola virus which causes small pox and its transmittable from person to person, the diagnosis of the disease has to be done accurately and the right treatment begun immediately (McCollum & Damon, 2014).

Furthermore, its aspects of social, economical and psychological aspect which are also disturbed by the disease in question for the affected individuals or community. The current historical and chronological perspectives, the virological and pathogenetic studies, clinical presentation and diagnosis, management and prevention of Monkeypox will be also discussed in this systematic review. In this article, an effort was made to present the comprehensive picture of monkeypox based on the current and future research which can be helpful in practice, formation of the health policies, and identification of the future perspectives of researched topic.

Remaining incontinent to the meaning of this sickness as the world grapples with the aftermaths of monkeypox's geographical spread is important. It is authors hope that this review will act as a reference for healthcare practitioners, Researchers and policymakers in a bid to enable relevant stakeholders to tide better and fashion out better responses to this emerging new infectious disease threat.

HISTORY AND EPIDEMIOLOGY

Monkeypox has a historical record associated with the smallpox virus which was brought to an end by the stopping of the massive smallpox vaccinations. This section will aim at comparing and contrasting the pre and post discovery of monkeypox and major events that define this disease.

DISCOVERY AND EARLY CASES:

Monkeypox virus was for the first time reported in 1958 from a group of sick cynomolgus monkeys that were under trial for polio vaccines in Copenhagen, Denmark. N. b. though the term monkey, these are not the natural hosts but as like human beings are considered to be the accidental hosts of the virus. The identity of the true reservoir species is still not clear; however, some data lead investigators to several species of rodents prevalent in Africa (Doty et al., 2017).

The first human case of the monkeypox was reported in 1970 in Zaire in a 9-month-old boy (Ladnyj et al., 1972). This case emerged during intensified efforts at scaling up smallpox elimination activities demonstrating clinical differentiation between monkeypox and smallpox as difficult. After this first case, other sporadic incidences of human infections were noted in several countries in Central and West Africa of which the largest number was reported in DRC (Fine et al., 1988).

GEOGRAPHIC DISTRIBUTION AND CLADES:

In the past, human monkeypox cases have been observed to occur in the remote parts of the tropical rainforest of central and western Africa. Two distinct genetic clades of the virus have been identified: It has been further split into two major groups namely Congo Basin (Central African) and West African. The Congo Basin clade has been known to be more virulent and become more transmissible from human to human than the West African clade (Beer & Rao, 2019).

NOTABLE OUTBREAKS:

1. DRC Endemic Transmission: In Africa, the Democratic Republic of Congo remains one of the countries that has the highest incidents of Monkeypox. Rising cases were seen after the termination of the customary smallpox vaccination in 1980; studies indicate that smallpox vaccines offered protection against monkeypox.
2. Nigeria Outbreak (2017-2018): Nigeria after almost 4 decades had no report of the disease until a major outbreak began in September last year. This outbreak was identified as the re-emergence of monkeypox in West Africa and extension of the new spatial distribution of the

disease (Yinka-Ogunleye et al. , 2019).

3. United States Outbreak (2003): African origin monkey pox first emerged in the United States; in 2003, associated with the importation of infected animals from Africa. This event illustrated how monkeypox could extend it area of distribution by the involvement of exotic pets trade (Reynolds et al. , 2007).

4. Global Outbreak (2022): In May of 2022, there was the first emrgency multi-country outbreak of monkeypox with cases presenting primarily in nations in which the virus is not continuously detected. This outbreak was associated with persistent person to person transmission including through contact and was primarily seen in MSM (Thornhill et al. , 2022).

CHANGING EPIDEMIOLOGY:

The epidemiology of monkeypox has shown significant changes over time:The epidemiology of monkeypox has shown significant changes over time:

1. Increased Incidence: Monkeypox is more prevalent than it was in the 1980s and is prevalent in the DRC. Several factors have been suggested as having caused this rise, and they include: cessation of smallpox vaccination, enhanced surveillance, ecological factors, and interaction of humans with animals (Bunge et al. , 2022).

2. Age Distribution Shift: Firstly, as with other infections, monkeypox used to affect children mainly. However, in more recent years, outbreaks have occurred in the adult group possibly because immunity levels resulting from previous campaigns for smallpox vaccination had wavered.

3. Transmission Patterns: Though the zoonotic transmission has been established and ongoing in all the three regions, recent outbreak showed person to person transmission, especially in densely-populated urban regions (Yinka-Ogunleye et al. , 2019).

4. Global Spread: The current global outbreak has spread the disease to several regions in the world at once indicating monkeypox hits many countries at once across the world – Europe, North America and South America, Africa and Asia (Kozlov, 2022).

CURRENT GLOBAL SITUATION:

Guaranteed as of 2023, monkeypox spreads across more than one hundred countries on the globe. Monkeypox received International Health Regulation's attention when the outbreak was listed as a Public Health Emergency of International Concern by the World Health Organization on July 23, 2022 (WHO, 2022). The further emerging epidemiology of monkeypox creates new problems for global public health systems. Knowledge of these changes is important in designing risk surveillance, control and prevention measures. On the current emerging situation, more research and surveillance studies are crucial approaches in order to detect further spread of monkeypox and respond appropriately.

DISCUSSION:

Knowledge on the monkeypox virus (MPXV) virology and pathogenesis remains critical for diagnostic, treatment and vaccine development. In the following section, a detailed description is provided regarding the nature of MPXV specific immunological properties molecular composition, its lytic cycle and pathogenicity in humans is documented.

VIRAL CHARACTERISTICS:

Monkeypox virus can be described as virus from the Orthopoxvirus group in the Poxviridae family. It is a double-stranded DNA virus which is large and enveloped and has a virion structure in the form of a brick (Moss, 2013). MPXV has a genome size of about 197 kb with about 190 predicted proteins or genes (Likos et al. , 2005). As with other members of the ortropox family, MPXV replicates in the cytoplasm of affected cells which is actually quite rare if not unique among DNA viruses.

Two distinct genetic clades of MPXV have been identified:Two distinct genetic clades of MPXV have been identified:

1. The Congo Basin (Central African) clade comprises Api, Ogowe, New Calabar, Old Calabar, Rio del Rey and especially the Ogooué.

2. The West African clade

The Congo Basin clade is reported to be evolved with greater virulence than the West African clade, and exhibits higher human-to-human transmission (Beer & Rao, 2019).

VIRAL REPLICATION CYCLE:

The MPXV replication cycle involves several stages:The MPXV replication cycle involves several stages:

1. Entry: MPXV infects mammalian cells by fusing with the plasma membrane or endocytosis. The specific receptors for MPXV are not identified, although orthopoxviruses are to interact with several receptors (Moss, 2016).
2. Uncoating: After entry into the cell the viral core migrates to the nucleus where it partially disassembles to embark viral DNA and early transcription factors.
3. Gene Expression: Expression of MPXV gene is sequential in the following way:

- Early genes: Produce proteins required for DNA-synthesis and mid-division intermediate on gene transcription.
- Intermediate genes: They are also involved in the production of the late gene transcriptions factors.
- Late genes: Synthesize structural proteins and enzymes which go to form the virion shell.

4. DNA Replication: As with all enveloped viruses, viral DNA replication takes place in the cytoplasm in factories that are distinct regions where the viral components are concentrated (Keck et al. , 1990).
5. Virion Assembly and Release: New virions are produced in the cytoplasm and are budding or sometimes mature MV by rupture or through secretion by budding.

PATHOGENESIS:

The pathogenesis of monkeypox involves several key steps:

1. Initial Infection: MPXV is normally contracted through penetration through the skin, via respiratory system or via the moist membranes in the mouth, anus, and genitals. The virus first multiplies at the site of deposition which is termed as replication site (Nishiura, 2012).
2. Primary Viremia: It starts at the primary site and then goes to the regional lymph nodes and from there it enters the blood stream and cause primary viremia.
3. Organ Seeding: It is evident that during viremia MPXV spreads to the skin, liver, as well as the spleen among other organs. This leads to a secondary viremia, which is characterised through onset of fever and other prodromal symptoms (McCollum & Damon, 2014).
4. Skin Lesions: The characteristic skin lesions of monkeypox progress as virus replicates basically in the epidermis of the skin. These lesions progress through stages: macules, papules, vesicles, pustules and scab formations are some of them according to Nishiura (2012).
5. Immune Response: One of the significant replies to managing an infection with MPXV is a host immune response. Both innate and adaptive immune responses are involved: Both innate and adaptive immune responses are involved:

- Innate Immunity: Natural killer cells and interferons stand in frontline in containing the virus during the first stages.
- Adaptive Immunity: Antiviral immunity through T-cell responses, especially CD8+ T-cells is important in elimination of viruses. Their response are subtle and appear later in the course of an infection and contribute to the memory or latent immunity (Hammarlund et al. , 2005).

6. Viral Immune Evasion: MPXV, like other poviruses, synthesizes many proteins involved either in modulation or evasion of host immune response. Examples are proteins that block complement activation, proteins that negatively regulate IFN signalling and proteins that control inflammation (Johnston & McFadden, 2017).

FACTORS INFLUENCING DISEASE SEVERITY:

Several factors can influence the severity of monkeypox infection:Several factors can influence the severity of monkeypox infection:

1. Viral Strain: Again, whilst the Congo Basin clade is expected to cause more severe disease than the West African clade, the impact of hydroxychlorine sulphate in West Africa has not been well established.

2. Route of Transmission: Covid-19 has respiratory transmission which can be more severe than cutaneous transmission depending on the situation (Reynolds et al. , 2019).
3. Dose of Virus: An evolutionary model applied to the case of pandemic influenza found that higher initial viral doses may be associated with increased virulence (Nishiura, 2012).
4. Host Factors: Some factors that determines the severity of the disease and the outcome include the age of the vaccinated person, his/her immunocompetence, and prior history of vaccination against smallpox.
5. Comorbidities: Coexisting medical conditions may worsen the process of monkeypox infection (Ogoina et al. , 2020).

Therefore, the basic knowledge regarding the virology and pathogenesis of MPXV is essential in order to launch proper treatment. With the new developments in molecular biology and animal model systems much has been discovered, but many fundamental issues regarding MPXV and host-pathogen interactions remain to be uncovered. Largest investment in research in these areas contines to go ahead in a race to find better diagnostic methods, new therapeutic interventions and ways of developing vaccines.

CLINICAL PRESENTATION:

Monkeypox in humans therefore presents with a cluster of signs and symptoms that progress through the stages of the disease. Knowledge of these clinical features especially helps in the early diagnosis, distinction from other diseases and correct handling of the disease.

INCUBATION PERIOD:

The duration which monkeypox takes to develop in an infected patient varies, and the average is 6-13 days, although it may take as little as 5 days or as long as 21 days (Patrono et al. , 2022). The duration of the incubation period may differ from path to path, from the route of transmission, from the initial viral load, or from some components of the host.

STAGES OF ILLNESS:

The clinical course of monkeypox can be divided into two main stages: these two early states of the illness: the prodromal phase and the exanthematous phase.

1. Prodromal Phase:

The prodromal phase usually lasts 1-5 days and is characterized by non-specific symptoms including:The prodromal phase usually lasts 1-5 days and is characterized by non-specific symptoms including:

- Fever, including high one (above 38,5 °C)
- Intense headache
- Lymphadenopathy (This differ from smallpox in that)
- Back pain
- Myalgia (muscle aches)
- Pure fatigue or intense asthenia

Monkeypox, like chickenpox, causes formation of skin lesions, however, lymphadenopathy is present in monkeypox and not in chickenpox or smallpox. The most frequently involved include the submandibular, cervical or inguinal node and depending on the development; the node may be generalized or localized.

2. Exanthematous Phase:

The exanthematous or rash phase is normally developed in 1-3 days after the onset of fever. The rash evolves through several stages:The rash evolves through several stages:

a) Macules: Skin becomes flat and loses its colour – at first the face is affected, then the rest of the body.
b) Papules: For a while the lesions become raised.
c) Vesicles: Epibulbar sclerotic cysts mature into clearer fluid-containing bullae.
d) Pustules: It fills up with white blood cells, bacteria, and other debris forming pus.
e) Scabs: The pustules then become covered in scab.
f) Desquamation: The scabs shed off and one is left with depigmented sites which they may repigment in future.

The development of rash from macules to desquamation usually last for about 2-4 weeks (McCollum & Damon, 2014).

DISTRIBUTION OF LESIONS:

In the classical form the rash starts on the face and spreads outwards in circles to involve the face, palms and soles. However, in recent outbreaks, particularly the 2022 global outbreak, atypical presentations have been observed: However, in recent outbreaks, particularly the 2022 global outbreak, atypical presentations have been observed:

- There seems to be a predilection for genital and perianal involvement and this is especially seen in MSMs (Thornhill et al. , 2022).
- It is also noteworthy that the supposed lesions might not necessarily be disseminated throughout the organism but most likely confined to the loci of inoculation.
- The number of lesions ranges between 1 to several thousands.
- Lesions can be active at different levels, stages and that was our challenge against the classical presentation in which we see all lesions are at the same stage of evolution.
-

OTHER CLINICAL FEATURES:

Additional symptoms and complications may include:

- Pharyngitis
- Cough
- Nausea and vomiting
- Diarrhea
- Proctitis, especially in the new outbreaks of the infection
- Conjunctivitis
- Keratitis

SEVERE COMPLICATIONS:

Most monkeypox infections are relatively mild and resolve independently, albeit with substantial morbidity; still, severe outcomes can happen in immunocompromised, postpubescent children, and pregnant females. These may include:

- Bacterial infections in the skin lesions secondaries
- Pneumonia
- Encephalitis
- Sepsis
- Blindness resulting from corneal scarring

Monkeypox can cause adverse outcomes in pregnancy such as spontaneous abortion and still birth among pregnant woman (Mbala et al. , 2017).

CLINICAL COURSE AND PROGNOSIS:

Monkeypox has a clinical course less severe than that of smallpox. It is typically not treated and most of the patients are usually well within 2 to 4 weeks. The CFR also differs by the viral clade; the Congo Basin clade has a higher CFR (up to 10%) than the West African clade (approximately 1%) (Beer & Rao, 2019).

Factors associated with poor prognosis include:

- Young age
- Immunosuppression
- Underlying medical conditions
- Many lesions
- Pregnancy

ATYPICAL PRESENTATIONS:

The 2022 global outbreak has highlighted several atypical clinical presentations:The 2022 global outbreak has highlighted several atypical clinical presentations:

- Lack of prodromal signs in some investigations
- Felty's & , localized dermatitis, most often in the anogenital area
- The existence of multiple lesions of various stage of evolution at the same time
- Proctitis as an important sign in some of the cases

These atypical presentations emphasise that there should always be a low threshold for considering monkeypox as one of the differential diagnoses for various rash conditions especially among the high risks groups or when exposed to relevant epidemiological triggers.

Awareness of the various manifestations of monkeypox is therefore important in considerations on how best to isolate affected individuals, and in the decision to commence supportive or specific treatment. Knowing this advanced pattern of monkeypox epidemiology, clinicians must be ready to consider every case they come across and be prepared to change their approach to diagnosing the disease and managing

the situation.

DIAGNOSIS:

Proper diagnosis of patient with monkeypox is significant for management of the patient, infection prevention and control measures, and epidemiological interventions. Monkeypox diagnosis is done clinically but depends on clinical presentation, epidemiological factors, and laboratory investigation.

CLINICAL DIAGNOSIS:

Clinical diagnosis is based on the characteristic presentation of monkeypox, including:Clinical diagnosis is based on the characteristic presentation of monkeypox, including:

- Skin lesions that are typical of a specific disease
- Lymphadenopathy
- Fever and all the other signs associated with the prodromal phase
- Such factors as demography/travel history, contact with infected people or animals.

Yet, clinical diagnosis alone cannot be done because monkeypox resembles other poxvirus diseases and vesicular rash conditions.

DIFFERENTIAL DIAGNOSIS:

The differential diagnosis of monkeypox includes:The differential diagnosis of monkeypox includes:

- Chickenpox (varicella-zoster virus)
- Smallpox (Variola major (an orthopoxvirus, although the disease has been eradicated))
- Herpes simplex virus infections
- Measles
- Scabies
- Secondary syphilis
- Drug eruptions
- There are also other purported noninfectious causes of vesiculopustular rashes

LABORATORY DIAGNOSIS:

In general, laboratory confirmation is critical in the diagnosis of monkeypox. Several methods are available:

1. Polymerase Chain Reaction (PCR):

Monkeypox diagnosis has been identified as using PCR as the standard measure. It is characterized by high sensitivity and specificity and allows distinguishing between orthopoxvirus species (Li et al., 2010).

- Sample types: Tissue samples from skin lesions (vesicular fluid or pustular material, crusts), nasopharyngeal swabs, serum.
- Real-time PCR assays can give a result within few hours.
- Can identify viral DNA before formation of antibodies is even identifiable

2. Electron Microscopy (EM):

EM can quickly detect the poxvirus particles in lesion sample but it cannot differentiate between different orthopoxviruses (Karem et al. , 2011).

- Is not as sensitive as PCR
- Need equipment and skills to be used in the course of offering the services.

3. Virus Isolation:

It is possible to isolate MPXV in cell culture but these procedures are lengthy and include securing of biosafety level 3 laboratory (Hutson et al., 2015 with protocal).

- helpful in ascertaining more qualities of the virus
- Currently not utilized for basic diagnosis because of time and safety issues.

4. Immunohistochemistry (IHC):

It has been seeking found that IHC can detect orthopoxvirus antigens in FF tissues (Hammarlund et al.; 2005,).

- Can useful for making diagnosis in retrospect or when it is impossible to obtain fresh samples.
- Is unable to differentiate between various orthopoxviruses

5. Serology:

Serological tests identify IgM and IgG antibodies against orthopoxviruses; however, the tests are not specific for monkeypox infection because they also cross react with antibodies resulting from smallpox vaccination or infection with other orthopoxviruses (McCollum & Damon, 2014).

- IgM and IgG antibodies were detected by using enzyme-linked immune-sorbent assay

(ELISA).
- Applicable for etiologic investigations and backward assessment of patient status.
- Not so useful in the acute phase diagnosis as the antibodies take time to produce.

6. Next-Generation Sequencing (NGS):
NGS can offer knowledge of the genomic background of the infecting MPXV strain including the strain circulating in the population at large (Kozlov, 2022).
- Turns out beneficial for outbreak investigations and studying the viruses' mutations.
- They are not frequently employed in diagnosing individual patients because it could be expensive as well as time consuming.

CHALLENGES:

1. Clinical Mimicry: Monkeypox can mimic other vesicular rash illnesses and get misdiagnosed or delayed diagnosis.
2. Atypical Presentations: Recent outbreaks have shown atypical presentations making clinical diagnosis harder (Adler et al., 2022).
3. Limited Resources: In endemic areas, limited access to advanced diagnostic tools can delay diagnosis.
4. Biosafety Concerns: Handling monkeypox specimens requires biosafety measures which may not be available in all settings.
5. Cross-reactivity: Serological tests may cross-react with antibodies from other orthopoxvirus infections or vaccinations.

DIAGNOSTIC ALGORITHMS:

To overcome these challenges, diagnostic algorithms have been proposed:
1. Initial clinical assessment and epidemiological history
2. Collection of appropriate specimens (lesion material, blood, nasopharyngeal swabs)
3. PCR testing for orthopoxviruses and specific MPXV detection
4. If PCR is negative but clinical suspicion remains high, consider additional testing (e.g., serology, repeat PCR)
5. In resource-limited settings, clinical diagnosis may guide initial management, with samples sent to reference laboratories for confirmation.

FUTURE DIRECTIONS:

Emerging diagnostic technologies will help improve monkeypox diagnosis:

1. Point-of-care molecular tests:
Rapid, field-deployable PCR or isothermal amplification assays can enhance early detection and outbreak control (Babonneau et al., 2022).

2. Multiplex assays:
Tests that can detect multiple pathogens causing similar clinical syndromes can aid in differential diagnosis.

3. Serological assays:
Development of monkeypox-specific serological tests can improve diagnosis and epidemiological surveillance.

4. Artificial intelligence:
Machine learning algorithms applied to clinical images can help in rapid screening and triage of suspected cases (Navarrete-Dechent et al., 2022).
Accurate and timely diagnosis of monkeypox is key to patient management and public health interventions. While PCR is the gold standard, combination of clinical assessment, epidemiological consideration and appropriate laboratory testing is essential for complete diagnosis. Ongoing research and development of new diagnostic tools will be crucial in addressing the evolving challenges of monkeypox outbreaks.

TREATMENT:

The control of monkeypox mostly entails supportive care, symptom control, and, in positive instances, the use of particular antiviral treatment options. As monkeypox is regularly self- limiting in immunocompetent people, remedy techniques may additionally range based on ailment severity, patient traits, and available resources.

SUPPORTIVE CARE:

For maximum sufferers with straight forward monkeypox, supportive care is the mainstay of treatment (McCollum & Damon, 2014). This

includes:

1. Fever control: Use of antipyretics which includes acetaminophen or ibuprofen.
2. Pain manage: Analgesics for myalgia, headache, and ache associated with pores and skin lesions.
3. Hydration: Ensuring adequate fluid intake, specifically if fever or mouth sores are gift.
4. Nutritional assist: Especially essential in sufferers with oral lesions that could impair ingesting.
5. Skin care: Keeping lesions smooth and dry to prevent secondary bacterial infections.
6. Pruritus management: Topical agents or oral antihistamines may be used for itch alleviation.

ANTIVIRAL THERAPIES:

While many instances of monkeypox resolve without particular antiviral treatment, positive antivirals can be considered, mainly for excessive instances or high-risk patients:

1. Tecovirimat (TPOXX):

- A novel antiviral that inhibits the viral envelope protein VP37, preventing the formation of enveloped virions (Grosenbach et al., 2018).
- Approved by means of the FDA for the treatment of smallpox and has been used for monkeypox beneath multiplied access protocols.
- Available in oral and intravenous formulations.
- Dosage: six hundred mg orally two times each day for 14 days (for adults ≥ 40 kg).

2. **Brincidofovir:**

- A lipid-conjugated analog of cidofovir that inhibits viral DNA polymerase (Quenelle et al., 2007).
- Has shown efficacy against orthopoxviruses in animal research.
- Not currently accredited for monkeypox however can be considered in medical trials or unique access packages.
-

3. **Cidofovir:**

- A nucleotide analog that inhibits viral DNA polymerase (De Clercq, 2002).
- Has been used for extreme cases of orthopoxvirus infections.
- Associated with sizeable renal toxicity, limiting its use.

4. Vaccinia Immune Globulin Intravenous (VIGIV):

- A hyperimmune globulin prepared from plasma of people immunized with smallpox vaccine (Hopkins & Lane, 2004).
- May be considered for excessive cases or in immunocompromised sufferers.
- Its efficacy in monkeypox remedy isn't nicely-hooked up.

TREATMENT CONSIDERATIONS:

The selection to apply antiviral therapy need to be based totally on several elements:

1. Disease severity: Antivirals are normally reserved for intense cases or those susceptible to severe ailment.
2. Patient traits: Immunocompromised people, pregnant girls, and children may be prioritized for antiviral remedy.
3. Timing: Early initiation of antivirals can be more powerful in changing disorder path.
4. Availability: Access to antivirals can be limited in a few settings.

MANAGEMENT OF COMPLICATIONS:

Specific headaches of monkeypox might also require extra interventions:

1. Secondary bacterial infections: Prompt initiation of suitable antibiotics based totally on culture and sensitivity consequences.
2. Ocular involvement: Ophthalmological evaluation and ability use of topical antivirals or antibiotics.
3. Respiratory complications: Oxygen remedy or mechanical ventilation may be required in severe instances.
4. Neurological headaches: Management of encephalitis or different CNS manifestations as in line with general protocols.

SPECIAL POPULATIONS:

1. Pregnant women: Limited records exists at the remedy of monkeypox in pregnancy. Management selections ought to stability maternal and fetal risks (Mbala et al., 2017).
2. Children: Dosing of antivirals should be adjusted based totally on weight. Close

monitoring for complications is essential.
3. Immunocompromised sufferers: May require extra competitive antiviral remedy and longer duration of treatment (Adler et al., 2022).

INFECTION CONTROL MEASURES:
While no longer strictly a remedy, infection manage is a important issue of monkeypox control:
1. Isolation: Patients need to be remoted until all lesions have crusted and fallen off.
2. Personal shielding system (PPE): Healthcare people must use suitable PPE.
Three. Environmental decontamination: Proper cleaning and disinfection of patient regions.

EMERGING THERAPIES:
Several capability cures are underneath investigation:
1. Monoclonal antibodies: Targeting unique viral proteins to neutralize the virus.
2. Novel antivirals: Compounds targeting diverse levels of the viral life cycle.
3. Immunomodulators: To decorate the host immune reaction towards the virus.

POST-EXPOSURE PROPHYLAXIS:
While now not a treatment for active sickness, submit-exposure prophylaxis with smallpox vaccination (inside four days of publicity) or antivirals can be taken into consideration for close contacts of confirmed cases (Petersen et al., 2019).

REVIEW:
As monkeypox continues to end up a international health problem, several regions require further research:
1. Optimization of antiviral regimens: Determining best dosing, length, and combos of antivirals.
2. Development of particular plans: monkeypox-treatment Targeted antivirals or immunotherapies.
3. Treatment strategies for special populations: Pregnant women, kids, and immunocompromised individuals.
4. Management of long-time period sequelae: Addressing capacity long-time period complications of monkeypox infection.
The remedy panorama for monkeypox is evolving hastily. While supportive care remains the cornerstone of management for lots sufferers, the function of particular antivirals is increasing, specially for excessive cases and high-chance individuals. Ongoing research and medical trials might be critical in refining remedy strategies and enhancing outcomes for sufferers with monkeypox.

Prevention and Control:
Effective prevention and control strategies are crucial in dealing with monkeypox outbreaks and lowering disease transmission. These techniques encompass a number of techniques, together with vaccination, public health measures, and wildlife management.

Vaccination:
1. **Smallpox Vaccines:**
Smallpox vaccines have shown cross-safety against monkeypox due to the genetic similarity between the viruses (Petersen et al., 2019).
A) First-generation vaccines (e.G., Dryvax):
- Live vaccinia virus vaccines used during smallpox eradication
- No longer in widespread use due to capability unfavorable outcomes
b) Second-era vaccines (e.G., ACAM2000):
- Live vaccinia virus vaccines derived from plaque purification of first-generation vaccines
- Approved for smallpox prevention but can be used for monkeypox underneath unique protocols
c) Third-technology vaccines (e.G., MVA-BN, LC16):
- Attenuated, non-replicating vaccines
- MVA-BN (marketed as Jynneos within the US, Imvanex in the EU) is permitted for both smallpox and monkeypox prevention
- Generally safer profile, especially for immunocompromised individuals

2. **Vaccination Strategies:**

a) Pre-exposure prophylaxis (PrEP):
- Recommended for laboratory employees dealing with orthopoxviruses and healthcare employees at high danger of exposure
b) Post-exposure prophylaxis (PEP):
- Vaccination inside four days of publicity can prevent disease onset
- Vaccination four-14 days publish-publicity might also reduce disorder severity (Rao et al., 2022)
c) Ring vaccination:
- Vaccination of close contacts of showed cases to create a buffer of immune people and save you in addition unfold.

Public Health Measures:
1. Surveillance and Case Detection:
- Active case finding and call tracing
- Enhanced surveillance in high-danger regions or populations
- Rapid reporting and records sharing among fitness government
2. **Isolation and Quarantine:**
- Isolation of confirmed and suspected cases until lesions have crusted and fallen off
- Quarantine of close contacts at some stage in the incubation length (up to 21 days)

3. **Risk Communication:**
- Clear, constant, and culturally suitable public health messaging
- Education on signs and symptoms, transmission routes, and prevention measures
- Combating incorrect information and stigma

4. **Infection Control in Healthcare Settings:**
- Implementation of general, touch, and droplet precautions
- Proper use of personal shielding equipment (PPE)
- Environmental cleansing and disinfection

5. **Travel-associated Measures:**
- Health screening at points of entry
- Travel advisories for affected areas
- Collaboration among countries for cross-border contact tracing
6. **Community Engagement:**
- Involving network leaders and companies in prevention efforts
- Addressing cultural practices that can increase transmission threat

WILDLIFE MANAGEMENT AND ZOONOTIC CONTROL:
1. Animal Surveillance:
- Monitoring of capacity animal reservoirs, in particular rodents in endemic areas
2. Regulation of Wildlife Trade:
- Stricter controls at the importation of distinguished animals
- Enforcement of rules at the puppy change, mainly for rodents from endemic areas
3. Human-Wildlife Interface Management:
- Reducing human contact with ability animal reservoirs
- Education on secure practices while handling natural world or bush meat
4. **One Health Approach:**
- Collaboration among human fitness, animal health, and environmental sectors to cope with the zoonotic nature of monkeypox

RESEARCH AND DEVELOPMENT:
1. Vaccine Development:
- Ongoing research into more powerful and more secure vaccines
- Development of thermostable formulations for use in aid-restrained settings
2. Diagnostic Tools:
- Development of rapid, point-of-care diagnostic exams
- Improvement of serological assays for surveillance functions
3. Antiviral Therapies:
- Research into new antiviral compounds and treatment strategies
- Optimization of current antivirals for monkeypox remedy
4. Epidemiological Studies:
- Investigation of transmission dynamics and risk elements
- Modelling research to tell manage techniques
5. Ecological Research:
- Studies on animal reservoirs and transmission cycles in nature

- Investigation of environmental factors influencing monkeypox emergence

CHALLENGES IN PREVENTION AND CONTROL:

1. Limited Vaccine Supply:
- Global shortages of smallpox/monkeypox vaccines at some point of the 2022 outbreak
2. Vaccine Hesitancy:
- Addressing concerns and misinformation about vaccine safety and efficacy
3. Stigma and Discrimination:
- Overcoming stigma associated with the sickness, in particular in affected communities
4. Resource Limitations:
- Inadequate healthcare infrastructure and resources in a few endemic areas

5. **Evolving Epidemiology:**
- Adapting manipulate measures to changing transmission patterns and affected populations

FUTURE DIRECTIONS:

1. **Global Coordination:**
- Strengthening global collaboration for surveillance, studies, and response

2. **Capacity Building:**
- Enhancing laboratory diagnostic capabilities and healthcare worker education in affected areas

3. **Sustainable Control Strategies:**
- Developing long-time period processes to manipulate monkeypox in endemic regions

4. **Integration with Existing Health Systems:**
- Incorporating monkeypox prevention and control into broader public fitness packages
5. Preparedness Planning:
- Developing and refining countrywide and international preparedness plans for monkeypox outbreaks.

Effective prevention and manage of monkeypox require a multifaceted approach combining vaccination, public health measures, and ecological interventions. As the worldwide state of affairs keeps to adapt, adaptability and ongoing research will be critical in refining those strategies and mitigating the impact of monkeypox outbreaks.

CURRENT RESEARCH AND FUTURE DIRECTIONS:

The international monkeypox outbreak of 2022 has intensified studies efforts throughout various domain names, from simple virology to public health interventions. This segment explores the modern-day studies panorama and capacity future instructions in monkeypox science and management.

Virology and Pathogenesis:

1. Genomic Studies:
- Ongoing complete-genome sequencing efforts to track viral evolution and unfold (Isidro et al., 2022).
- Investigation of genetic elements contributing to expanded human-to-human transmission.

2. **Host-Pathogen Interactions:**
- Research into cellular receptors and entry mechanisms of monkeypox virus.
- Studies on viral immune evasion strategies and host immune responses. Three. Animal Models:
- Development and refinement of animal models for reading monkeypox pathogenesis and trying out interventions (Hutson et al., 2015).

4. **Transmission Dynamics:**
- Investigation of factors influencing human-to-human transmission.
- Studies on ability airborne transmission and environmental stability of the virus.

Diagnostics:

1. Rapid Testing:
- Development of point-of-care molecular exams for short and accurate prognosis.
- Exploration of CRISPR-based totally diagnostic tools for monkeypox detection (Kushwaha et al., 2022).
2. Serological Assays:
- Improvement of serological checks to differentiate among monkeypox contamination and vaccination.
- Development of assays for populace-degree seroprevalence research.

3. Multiplexed Diagnostics:
- Creation of checks that may simultaneously stumble on multiple poxviruses or differentiate among poxviruses and other reasons of vesicular rashes.
4. AI-Assisted Diagnosis:
- Development of gadget gaining knowledge of algorithms for computerized evaluation of medical pix to aid in analysis (Navarrete-Dechent et al., 2022).

Therapeutics:
1. Antiviral Drug Development:
- Screening of compound libraries for novel anti-monkeypox dealers.
- Optimization of existing antivirals like tecovirimat for monkeypox treatment.
2. Immunotherapies:
- Development of monoclonal antibodies concentrated on unique monkeypox virus proteins.
- Exploration of cytokine modulators to manipulate severe sickness.

3. Combination Therapies:
- Investigation of synergistic results between distinct antivirals or antivirals and mmunotherapies.
4. Drug Repurposing:
- Screening of permitted drugs for ability efficacy towards monkeypox.

VACCINES:
1. Next-Generation Vaccines:
- Development of monkeypox-unique vaccines with stepped forward safety and efficacy profiles.
- Research into novel vaccine structures, which include mRNA-based vaccines for poxviruses.
2. Dose-Sparing Strategies:
- Investigation of fractional dosing to increase vaccine deliver (Rao et al., 2022).
- Studies on intradermal vaccine administration for dose optimization.
3. Vaccine Efficacy:
- Long-time period studies on the length of vaccine-caused immunity.
- Research on vaccine effectiveness against one of a kind monkeypox clades.
4. Universal Poxvirus Vaccines:
- Exploration of vaccine candidates that could offer vast safety towards multiple poxviruses.

EPIDEMIOLOGY AND PUBLIC HEALTH:
1. Transmission Studies:
- Investigation of transmission chains and danger elements in non-endemic outbreaks.
- Research at the role of asymptomatic or pre-symptomatic transmission.
2. Modeling and Forecasting:
- Development of stepped forward mathematical fashions for predicting outbreak dynamics and evaluating manipulate measures (Johnson et al., 2023).
3. One Health Approaches:
- Integrated research on human, animal, and environmental factors in monkeypox ecology.
- Investigation of zoonotic spillover activities and prevention strategies.
4. Health Systems Research:
- Studies on healthcare preparedness and reaction capacities for monkeypox outbreaks.
- Evaluation of public fitness interventions and manage techniques.
5. Social Science Research:
- Investigation of behavioral elements influencing sickness spread and manage measure adherence.
- Studies on stigma and its effect on case reporting and healthcare seeking.

CLINICAL RESEARCH:
1. Natural History Studies:
- Long-time period follow-up of monkeypox sufferers to understand ability sequelae.
- Investigation of things influencing sickness severity and effects.
2. Clinical Trials:
- Randomized controlled trials of antivirals and different healing interventions.
- Studies on submit-exposure prophylaxis strategies.
3. Special Populations:
- Research on monkeypox in being pregnant, pediatric populations, and immunocompromised people.
4. Biomarkers:

- Identification of prognostic biomarkers for excessive disorder.
- Development of markers for treatment reaction monitoring.

FUTURE DIRECTIONS:

1. Global Collaboration:
- Establishment of worldwide research networks for coordinated studies and information sharing.
- Capacity constructing for monkeypox studies in endemic international locations.
2. Technological Integration:
- Application of massive information analytics and synthetic intelligence in monkeypox surveillance and research.
- Use of genomic epidemiology tools for real-time outbreak tracking.
3. Preparedness and Response:
- Development of frameworks for rapid research activation in the course of destiny outbreaks.
- Integration of monkeypox into broader rising disease preparedness plans.
4. Ethical Considerations:
- Addressing moral problems in monkeypox studies, specially in vulnerable populations.
- Ensuring equitable get right of entry to to analyze participation and blessings.
5. Translational Research:
- Accelerating the interpretation of primary science findings into clinical applications.
- Development of novel interventions based on stepped forward understanding of monkeypox biology.

The monkeypox research panorama is rapidly evolving, driven by using the urgency of recent outbreaks and technological improvements. Future studies efforts will in all likelihood recognition on growing more effective diagnostics, therapeutics, and vaccines, while also deepening our expertise of the virus's biology and ecology. Interdisciplinary collaboration and sustained investment can be vital in addressing the final know-how gaps and growing comprehensive techniques to control monkeypox as an emerging worldwide health risk.

CONCLUSION:

Monkeypox, once considered an extraordinary and geographically restricted zoonotic disorder, has emerged as a sizeable international health difficulty. The remarkable multi-united states outbreak in 2022 has highlighted the capability for this virus to purpose enormous human-to-human transmission past its traditional endemic areas. This complete overview has explored the various sides of monkeypox, from its historic context and virology to cutting-edge management strategies and future studies directions. The evolving epidemiology of monkeypox offers new challenges for public fitness systems worldwide. The shift from in general zoonotic transmission in rural African settings to sustained human-to-human unfold in various international populations necessitates a re evaluation of our approach to prevention, analysis, and control. The bizarre medical presentations determined in recent outbreaks underscore the importance of keeping a excessive index of suspicion and thinking about monkeypox inside the differential analysis of various rash ailments, specifically in high-chance populations.

Advances in molecular diagnostics have advanced our ability to unexpectedly and accurately perceive monkeypox infections. However, the need for point-of-care trying out and improved serological assays remains essential, especially in resource-confined settings. The development and deployment of 1/3-technology smallpox vaccines have furnished a treasured device for prevention and post-publicity prophylaxis, even though demanding situations in supply and distribution persist. Treatment strategies for monkeypox hold to adapt. While supportive care remains the cornerstone of management for lots sufferers, the function of unique antivirals is increasing, specially for extreme instances and excessive-threat people. The current approval and use of tecovirimat constitute a big develop in centre remedy for orthopoxvirus infections, including monkeypox. Prevention and manipulate techniques should adapt to the converting epidemiology of the disorder. Ring vaccination, stronger surveillance, and sturdy contact tracing have verified effective in containing outbreaks. However, the global nature of the recent outbreak

highlights the need for worldwide cooperation and coordinated reaction efforts.

The studies landscape for monkeypox is rapidly expanding, pushed through the urgency of latest occasions and technological advancements. Priority areas for future studies consist of the improvement of stepped forward diagnostics, novel therapeutics, and next-technology vaccines. Additionally, a deeper knowledge of the virus's molecular biology, transmission dynamics, and ecological factors influencing its emergence is vital for growing comprehensive manipulate strategies. As we circulate forward, a One Health approach, spotting the interconnectedness of human, animal, and environmental fitness, could be crucial in addressing the complex demanding situations posed with the aid of monkeypox. This method have to tell each research initiatives and public fitness interventions. The worldwide response to monkeypox will require sustained dedication from the scientific network, healthcare vendors, policymakers, and the public. Continued investment in studies, surveillance, and healthcare infrastructure, particularly in endemic regions, is vital. Moreover, efforts to combat stigma and ensure equitable get right of entry to prevention and treatment resources need to remain at the forefront of worldwide fitness tasks.

In conclusion, whilst big progress has been made in our expertise and control of monkeypox, many demanding situations remain. The current global outbreak serves as a reminder of the ability for emerging infectious diseases to motive full-size impact and the importance of ongoing vigilance and preparedness. By constructing on modern understanding, addressing research gaps, and fostering worldwide collaboration, we are able to paintings toward extra effective strategies to prevent, control, and in the long run mitigate the impact of monkeypox on worldwide fitness.

REFERENCES:

Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., ... & Larbalestier, N. (2022). Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases, 22(8), 1153-1162.

Babonneau, J., Brichler, S., Jérôme, G., Nyanabo, N. L., Poirier, E., Queval, C., ... & Piorkowski, G. (2022). Rapid detection of monkeypox virus using a real-time loop-mediated isothermal amplification assay. Journal of Clinical Virology, 156, 105280.

Beer, E. M., & Rao, V. B. (2019). A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Neglected Tropical Diseases, 13(10), e0007791.

Breman, J. G., Kalisa, R., Steniowski, M. V., Zanotto, E., Gromyko, A. I., & Arita, I. (1980). Human monkeypox, 1970-79. Bulletin of the World Health Organization, 58(2), 165.

Bunge, E. M., Hoet, B., Chen, L., Lienert, F., Weidenthaler, H., Baer, L. R., & Steffen, R. (2022). The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Neglected Tropical Diseases, 16(2), e0010141.

De Clercq, E. (2002). Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends in Pharmacological Sciences, 23(10), 456-458.

Doty, J. B., Malekani, J. M., Kalemba, L. N., Stanley, W. T., Monroe, B. P., Nakazawa, Y. U., ... & Carroll, D. S. (2017). Assessing monkeypox virus prevalence in small mammals at the human–animal interface in the Democratic Republic of the Congo. Viruses, 9(10), 283.

Fine, P. E., Jezek, Z., Grab, B., & Dixon, H. (1988). The transmission potential of monkeypox virus in human populations. International Journal of Epidemiology, 17(3), 643-650.

Grosenbach, D. W., Honeychurch, K., Rose, E. A., Chinsangaram, J., Frimm, A., Maiti, B., ... & Hruby, D. E. (2018). Oral tecovirimat for the treatment of smallpox. New England Journal of Medicine, 379(1), 44-53.

Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., ... & Slifka, M. K. (2003). Duration of antiviral immunity after smallpox vaccination. Nature Medicine, 9(9), 1131-1137.

Hopkins, R. J., & Lane, J. M. (2004). Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clinical Infectious Diseases, 39(6), 819-826.

Hutson, C. L., Carroll, D. S., Self, J., Weiss, S., Hughes, C. M., Braden, Z., ... & Damon,

I. K. (2015). Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease. Virology, 481, 161-170.

Isidro, J., Borges, V., Pinto, M., Sobral, D., Santos, J. D., Nunes, A., ... & Gomes, J. P. (2022). Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nature Medicine, 28(8), 1569-1572.

Johnson, R., Johnson, P., & Kuhanendran, D. (2023). Monkeypox epidemic simulations to inform transmission dynamics and public health interventions. Nature Communications, 14(1), 1-12.

Johnston, J. B., & McFadden, G. (2017). Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cellular Microbiology, 19(7), e12730.

Karem, K. L., Reynolds, M., Braden, Z., Lou, G., Bernard, N., Patton, J., & Damon, I.

K. (2011). characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clinical and Diagnostic Laboratory Immunology, 12(7), 867-872.

Keck, J. G., Baldick, C. J., & Moss, B. (1990). Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell, 61(5), 801-809.

Kozlov, M. (2022). Monkeypox goes global: why scientists are on alert. Nature, 606(7912), 15-16.

Kushwaha, A., Singla, R., Mehra, R., Kumar, R., Adhikari, P., & Agrawal, A. (2022).

CRISPR-based diagnosis of monkeypox: strategies and challenges. Journal of Medical Virology, 94(12), 5463-5467.

Ladnyj, I. D., Ziegler, P., & Kima, E. (1972). A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bulletin of the World Health Organization, 46(5), 593.

Li, Y., Zhao, H., Wilkins, K., Hughes, C., & Damon, I. K. (2010). Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. Journal of Virological Methods, 169(1), 223-227.

Likos, A. M., Sammons, S. A., Olson, V. A., Frace, A. M., Li, Y., Olsen-Rasmussen, M.,

... & Damon, I. K. (2005). A tale of two clades: monkeypox viruses. Journal of General Virology, 86(10), 2661-2672.

Mbala, P. K., Huggins, J. W., Riu-Rovira, T., Ahuka, S. M., Mulembakani, P., Rimoin,

A. W., ... & Muyembe-Tamfum, J. J. (2017). Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. The Journal of Infectious Diseases, 216(7), 824-828.

McCollum, A. M., & Damon, I. K. (2014). Human monkeypox. Clinical Infectious Diseases, 58(2), 260-267.

Moss, B. (2013). Poxvirus DNA replication. Cold Spring Harbor Perspectives in Biology, 5(9), a010199.

Moss, B. (2016). Poxvirus entry and membrane fusion. Virology, 479, 619-626.

Navarrete-Dechent, C., Lezcano, C., Armayor, M., Chu, E. Y., & Granter, S. R. (2022).

Computer-assisted diagnosis of monkeypox using artificial intelligence. JAMA Dermatology, 158(9), 1078-1079.

Nishiura, H. (2012). Determination of the appropriate quarantine period following smallpox exposure: an objective approach using the incubation period distribution. International Journal of Hygiene and Environmental Health, 215(1), 27-31.

Ogoina, D., Iroezindu, M., James, H. I., Oladokun, R., Yinka-Ogunleye, A., Wakama, P., ... & Musa, B. O. (2020). Clinical course and outcome of human monkeypox in Nigeria. Clinical Infectious Diseases, 71(8), e210-e214.

Patrono, L. V., Pléh, K., Samuni, L., Ulrich, M., Röthemeier, C., Sachse, A., ... & Leendertz, F. H. (2020). Monkeypox virus emergence in wild chimpanzees reveals distinct clinical outcomes and viral diversity. Nature Microbiology, 5(7), 955-965.

Petersen, E., Kantele, A., Koopmans, M., Asogun, D., Yinka-Ogunleye, A., Ihekweazu, C., & Zumla, A. (2019). Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infectious Disease Clinics, 33(4), 1027-1043.

Quenelle, D. C., Prichard, M. N., Keith, K. A., Hruby, D. E., Jordan, R., Painter, G. R., ... & Kern, E. R. (2007). Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrobial Agents and Chemotherapy, 51(11), 4118-4124.

Rao, A. K., Schulte, J., Chen, T. H., Hughes, C. M., Davidson, W., Neff, J. M., ... & Petersen, B. W. (2022). Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. Morbidity and Mortality Weekly Report, 71(22), 734.

Reynolds, M. G., Davidson, W. B., Curns, A. T., Conover, C. S., Huhn, G., Davis, J. P., ... & Damon, I. K. (2007). Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerging Infectious Diseases, 13(9), 1332.

Reynolds, M. G., McCollum, A. M., Nguete, B., Shongo Lushima, R., & Petersen, B. W. (2019). Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses, 11(4), 380.

Rimoin, A. W., Mulembakani, P. M., Johnston, S. C., Lloyd Smith, J. O., Kisalu, N. K., Kinkela, T. L., ... & Muyembe, J. J. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences, 107(37), 16262- 16267.

Sklenovská, N., & Van Ranst, M. (2018). Emergence of monkeypox as the most important orthopoxvirus infection in humans. Frontiers in Public Health, 6, 241.

Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., ... & Orkin, C. (2022). Monkeypox virus infection in humans across 16 countries—April–June 2022. New England Journal of Medicine, 387(8), 679-691.

von Magnus, P., Andersen, E. K., Petersen, K. B., & Birch-Andersen, A. (1959). A pox- like disease in cynomolgus monkeys. Acta Pathologica Microbiologica Scandinavica, 46(2), 156-176.

World Health Organization. (2022). Multi-country monkeypox outbreak: situation update.

Yinka-Ogunleye, A., Aruna, O., Dalhat, M., Ogoina, D., McCollum, A., Disu, Y., ... & Ihekweazu, C. (2019). Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. The Lancet Infectious Diseases, 19(8), 872-879